Dấu hiệu nhận biết lũ quét và hướng dẫn kỹ năng an toàn phòng tránh https://tnnet.vn/dau-hieu-nhan-biet-lu-quet-va-huong-dan-ky-nang-an-toan-phong-tranh

Probiotics in Animal Feed Market Size 2025 Top Companies, Trend Analysis, Current Growth, Business Strategy and Forecast 2032 Internet of Things (IoT) in the Energy Market was valued at approximately USD 26.7 billion in 2023, and is expected to grow to USD 75.0 billion by 2032, registering a CAGR of ~12.2% from 2024 to 2032 These numbers reflect the accelerating integration of connected thermostats, sensors, and AI-driven analytics across utilities, renewables, and industrial energy applications. Request Free Sample Report:https://www.stellarmr.com/report/req_sample/Internet-of-Things--IoT--in-the-Energy-Market/400 Market Estimation, Growth Drivers & Opportunities IoT solutions include smart meters, sensor networks, platforms, analytics software, and cybersecurity services—deployed in smart grids, oil & gas, digital oilfields, coal mining, and more  Key growth drivers: Smart-grid modernization: Utilities worldwide are deploying real-time fault detection, automated meter management, and demand response systems  AI/ML integration: Embedded cognitive tools now enable predictive maintenance and proactive grid operations . Renewables & DER integration: IoT is vital for managing distributed energy resources and enhancing grid flexibility Cybersecurity demands: Rising cyber threats have increased investment in IoT security, a fast-growing subsegment IoT telecom advances: Cellular (including NB-IoT), satellite, and private 5G networks are enabling robust connectivity. Opportunities lie in deploying IoT in EV charging networks, behind-the-meter systems, virtual power plants, decarbonized transmission infrastructure, and emissions monitoring platforms. U.S. Market: Trends & Investment The U.S. IoT-in-energy market was estimated at USD 8.4 billion in 2024, projected to reach USD 31.5 billion by 2034 (CAGR ~14.2%)  Key developments: Grid resilience initiatives: Federal and state pilot programs are supporting IoT-enabled substation upgrades and DER integration . AI-powered grid modernization: Utilities like Duke Energy are piloting predictive analytics with IoT sensors to identify transformer faults and reduce outages  Private sector tech investment: BP Energy Partners recently backed Smart Wires with USD 65 million to deploy IoT-enabled power-flow control for utilities in the U.S. and UK. Support for data center growth: Driven by AI-led electricity demand, utilities are expanding IoT infrastructure to maintain reliability in data-center hotspots Market Segmentation: Leading Segments By Application: Smart grid leads with ~38–39% share in 2024, driven by real-time monitoring and grid-edge intelligence. Oil & gas and coal mining are significant sectors, with IoT used for asset health and operational safety  By Component: Hardware platforms accounted for ~41% spending in 2024. Security services are the fastest-growing software subsegment (CAGR ~17.9%). By Connectivity: Cellular/NB-IoT dominates current network deployments, while private 5G and satellite connectivity are gaining traction  By Deployment: On-premise systems remain essential for utilities requiring high security. Cloud-based platforms are the fastest-growing model, offering scalability and AI analytics Competitive Analysis: Top 5 Companies 1. Siemens AG – Provides grid IoT platforms (MindSphere) and sensor-to-cloud solutions for utilities worldwide. 2. IBM – Delivers Maximo Asset Monitor and Watson IoT to utilities for asset management and predictive maintenance  3. Cisco – Offers industrial IoT network infrastructure used by energy providers for secure, edge-to-cloud connectivity  4. Honeywell – Combines IoT, AI, and 5G in their Forge.AI platform, supporting energy asset monitoring globally, including utility pilots in India and North America  5. Itron – A leader in smart meters and AMI solutions, integrating IoT with demand-response tools used by utilities worldwide  Other major players include Schneider Electric, ABB, GE, Oracle, and Rockwell Automation—spanning hardware, analytics, connectivity, and security offerings  Regional Analysis: USA, UK, Germany, France, Japan, China United States (~37% global IoT energy share): Leading grid modernization efforts, regulatory backing, and investments in pilot programs and data-center grid resilience . UK & Europe (Germany, France): Benefit from the Energy Independence and Security Act, FERC mandates, and EU-level carbon compliance—leading to high IoT adoption in smart grids and renewables  China: Strong APAC IoT-in-energy growth (~36% share) due to focus on smart meter deployment, DER integration, and 5G connectivity  Japan: IoT use is rising in commercial buildings and microgrid pilot programs as part of national energy efficiency goals. Conclusion The IoT in Energy Market is on track to skyrocket—from USD 26.7 billion in 2023 to USD 75 billion by 2032, growing at ~12% CAGR Its expansion is fueled by smart-grid modernization, AI/ML-enabled analytics, DER integration, cybersecurity needs, and data-driven operational excellence. Strategic opportunities include: Broad deployment of AI-powered predictive maintenance across grid assets. Scaling IoT-enabled EV charging networks and virtual power plant platforms. Rolling out cloud-native analytics for distributed renewables and behind-the-meter systems. Adoption of hybrid connectivity—combining cellular, 5G, and satellite—for universal coverage. Advancing cybersecurity and regulatory compliance to secure the increasingly connected energy system. About us Phase 3,Navale IT Zone, S.No. 51/2A/2, Office No. 202, 2nd floor, Near, Navale Brg,Narhe, Pune, Maharashtra 411041 +91 9607365656 [email protected]

How Do I Speak to Someone at Iceland Air? | Customer Help Line +1-888-355-9951 If you're wondering how do I speak to a live person at Iceland Air, simply call +1-888-355-9951 for round-the-clock support. If you need help with things like trip changes, delays, lost bags, or anything else, Iceland Air's customer service team is available 24 hours a day, seven days a week. Talk to a live person who knows what they're doing and can solve your problem right away. No more waiting for hours on end—this is the quick and simple way to get help with your trip plans. Blog URL: - https://farensky.com/blogs/how-do-i-talk-to-a-live-person-at-iceland-air/ Phone/Mobile: - +1-888-355-9951 Add: - 495 Route 70, Brick, NJ 08723 United States

Hướng dẫn kỹ năng an toàn SAU bão cho cộng đồng dân cư https://tnnet.vn/huong-dan-ky-nang-an-toan-sau-bao-cho-cong-dong-dan-cu

Áp dụng thành công kỹ thuật dung hòa miễn dịch trong ghép tế bào gốc đồng loại bất đồng nhóm máu https://tnnet.vn/ap-dung-thanh-cong-ky-thuat-dung-hoa-mien-dich-trong-ghep-te-bao-goc-dong-loai-bat-dong-nhom-mau

How Do I Talk to Someone at Norse? | Get Quick Quotes – Farensky Need help and wondering How do I speak to someone at Norse? Just dial +1-888-355-9951 to talk to a real person. From flight modifications to booking assistance, get round-the-clock support with friendly and professional guidance. Get 24/7 Travel Assistance – Dial +1-888-355-9951 Today 🌐 Support Available at United States: https://farensky.com/blogs/how-do-i-talk-to-a-someone-at-norse/

(Real Human) How Do I Talk to Norse Atlantic? | 24/7 Support – Call Now How do I talk to a human at Norse? Call +1-888-355-9951 to speak with a live agent instantly. Whether it’s for flight booking, changes, or cancellations, Expedia customer service is available 24/7 to help you with all travel-related issues. Get 24/7 Travel Assistance – Dial +1-888-355-9951 Today 🌐 Support Available at United States: https://farensky.com/blogs/how-do-i-talk-to-a-someone-at-norse/

Kỹ năng an toàn trước khi có lũ, ngập lụt https://tnnet.vn/ky-nang-an-toan-truoc-khi-co-lu-ngap-lut

Hướng dẫn kỹ năng ứng phó với bão số 3 và mưa lũ sau bão https://tnnet.vn/huong-dan-ky-nang-ung-pho-voi-bao-so-3-va-mua-lu-sau-bao

Intravenous Iron Drugs Market to be Driven by increasing population in the Forecast Period of 2025-2032 Intravenous (IV) Iron Drugs Market is poised for substantial growth, projected to expand from USD 3.29 billion in 2023 to approximately USD 6.15 billion by 2032, growing at a CAGR of 7.08% during the forecast period. The market’s upward trajectory is fueled by a surge in iron deficiency anemia (IDA) cases, increasing chronic kidney disease (CKD) incidences, growing preference for IV therapy, and continuous pharmaceutical innovation in iron formulations. Request Free Sample Report:https://www.stellarmr.com/report/req_sample/Intravenous-Iron-Drugs-Market/360 Market Estimation, Growth Drivers & Opportunities Iron deficiency affects nearly a third of the global population, and intravenous iron therapy has emerged as a preferred treatment in cases where oral iron supplements are ineffective or intolerable. IV iron drugs offer fast correction of iron deficiency and are especially crucial for patients with CKD, inflammatory bowel disease, cancer, or heart failure. Key Growth Drivers: Rising Global Anemia Burden: WHO estimates indicate that over 30% of women of reproductive age suffer from anemia, prompting a strong demand for efficient treatment options such as IV iron formulations. Prevalence of Chronic Kidney Disease (CKD): Patients undergoing dialysis frequently require IV iron therapy to manage anemia, making this segment a major driver of market growth. Surging Geriatric Population: Older adults are more prone to malnutrition and anemia, creating a robust demand pool for iron supplementation through parenteral routes. Technological Advancements in Formulation: Next-generation IV iron drugs with reduced dosing frequency, lower risk of hypersensitivity, and enhanced bioavailability are transforming clinical protocols. Opportunities: Emerging Markets: Increasing awareness and healthcare access in Asia-Pacific, Latin America, and the Middle East present untapped opportunities. Hospital-Based Infusion Services: The growth of specialty infusion clinics and hospital networks is enhancing the delivery of IV iron therapies in outpatient settings. U.S. Market Trends and Investment Scenario In the United States, IV iron drugs are witnessing increased adoption due to the high prevalence of anemia among CKD and cancer patients. The U.S. healthcare system's shift towards value-based care is favoring treatments that improve patient outcomes quickly and efficiently—such as ferric carboxymaltose and ferumoxytol. As of 2024, the FDA approved expanded indications for some IV iron therapies, such as Injectafer (ferric carboxymaltose), enhancing its use in broader patient segments. Additionally, investments from pharmaceutical giants like Pfizer and CSL Vifor are directed towards clinical trials and new product lines focusing on safer iron delivery with fewer side effects. Moreover, U.S.-based infusion centers are increasing their partnerships with insurance companies and Medicare/Medicaid, simplifying patient access to high-cost parenteral iron therapies, further boosting market penetration. Market Segmentation (Leading Share Segments Only) By Product Type: Ferric Carboxymaltose (FCM) holds the largest market share due to its high efficacy, favorable safety profile, and reduced infusion time, making it a preferred choice among healthcare providers. By Application: Chronic Kidney Disease (CKD) dominates the application segment. A high percentage of dialysis patients receive IV iron to manage anemia, particularly in the later stages of CKD. By End-User: Hospitals and Clinics remain the largest end-user segment. The availability of specialized staff and infrastructure for IV drug administration contributes to their dominance. Competitive Analysis: Top 5 Key Players 1. Vifor Pharma (a CSL Company) A leader in the IV iron space, CSL Vifor markets Injectafer and Venofer, two of the most widely used IV iron therapies. The company is actively investing in expanding label indications and strengthening global distribution. 2. Daiichi Sankyo Company, Ltd. Daiichi’s Injectafer (Ferinject) continues to gain international traction. The firm is exploring new applications beyond CKD and IDA, including postpartum anemia and chemotherapy-induced anemia. 3. Pfizer Inc. Pfizer’s commitment to hematology includes R&D investments in improving iron-carbohydrate complex formulations to ensure faster absorption and minimal side effects. The company is expected to introduce next-gen formulations with single-dose effectiveness. 4. AMAG Pharmaceuticals (acquired by Covis Pharma) AMAG’s Feraheme (ferumoxytol) is a significant player in the U.S. market. It is approved for adult patients with IDA who have intolerance to oral iron. Recent innovation focuses on reducing allergic reactions associated with IV iron therapy. 5. Rockwell Medical, Inc. Rockwell offers Triferic, an iron-replacement therapy used in dialysis patients. Their focus on developing cost-effective solutions and expanding into international markets has kept them competitive in a niche segment. These companies are investing in clinical trials, dosage optimization, and patient-focused delivery solutions to boost adoption. They are also exploring novel carriers and iron complexes that offer enhanced safety profiles, supporting long-term growth. Regional Insights United States: Accounts for the largest share of the global IV iron drugs market. Favorable reimbursement policies, advanced healthcare infrastructure, and high diagnosis rates of anemia are the key growth drivers. FDA approvals and fast-track processes for innovative iron therapies further fuel the U.S. market. United Kingdom: The National Health Service (NHS) promotes the use of IV iron in CKD and inflammatory conditions. Government-funded treatment protocols for pregnant women and elderly patients with iron deficiency are supporting steady market expansion. Germany: Germany’s highly structured hospital-based treatment systems and physician adherence to European Renal Best Practice Guidelines contribute to high adoption of IV iron drugs. Local manufacturers and research initiatives are supporting growth in biosimilar IV iron drugs. France: Government initiatives to improve women’s health and anemia management in cancer and surgical patients are fueling the demand for IV iron drugs. Strict regulations ensure high safety standards for these therapies. Japan: The aging population and high anemia rates in dialysis patients are increasing the demand for IV iron. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is encouraging clinical trials and approvals for new formulations. China: With improving healthcare access and awareness, China is rapidly adopting IV iron drugs in urban hospitals. The market is expanding through partnerships between multinational pharma companies and local distributors. China's updated essential drug list now includes modern IV iron formulations, further supporting access. Conclusion The Intravenous Iron Drugs Market is on a promising growth path due to rising anemia prevalence, advancements in parenteral formulations, and favorable healthcare policies globally. Innovations in drug formulation that reduce infusion times and minimize adverse reactions are revolutionizing the market landscape. About us Phase 3,Navale IT Zone, S.No. 51/2A/2, Office No. 202, 2nd floor, Near, Navale Brg,Narhe, Pune, Maharashtra 411041 +91 9607365656 [email protected]